Body composition as a predictor of toxicity after treatment with eribulin for advanced soft tissue sarcoma
- 92 Downloads
Despite the clinical benefits of eribulin on overall survival of advanced soft tissue sarcoma (STS) patients, treatment-related toxicity reduces their QOL. Body composition metrics (BCMs) are associated with poor outcome and drug toxicities in several cancers. This study investigated whether BCMs could predict drug toxicity occurrence in advanced STS patients treated with eribulin.
This study included 23 advanced STS patients treated with eribulin between March 2016 and April 2018. BCMs were evaluated using a CT scan obtained within 1 month before or after treatment initiation. The relationship of BCMs and other clinical factors was evaluated and CART analysis used to develop classification models for risk groups of drug toxicity.
Sixteen patients (69.6%) experienced any grade 3/4 toxicity. Eleven patients (47.8%) developed G4 hematologic toxicity, which was significantly higher in those with low skeletal muscle gauge (SMG) (P = 0.02) and low pretreatment neutrophil count (P = 0.0002). Six patients (26.1%) had grade 3/4 non-hematologic toxicity, and was higher in those with low SMG (P = 0.004), and low serum albumin level (P = 0.02). Five patients with high BMI (P = 0.03) experienced febrile neutropenia (FN) and low pretreatment neutrophil count (P = 0.02). CART analysis classified three risk groups, and area under the receiver operating characteristic curve (AUROCC) was 0.92, 0.88, 0.92 in G4 hematologic AE, G3/4 non-hematologic AE, FN, respectively.
SMG is a significant predictive factor of eribulin drug toxicity in advanced STS patients. Risk classification of drug toxicity through combining predictive factors, could improve the therapeutic strategy used in chemotherapy.
KeywordsAdvanced soft tissue sarcoma Eribulin Body composition metrics Toxicity
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
Compliance with ethical standards
Conflict of interest
All authors declare that there are no conflicts of interest relevant to this manuscript.
- 5.Callegaro D, Miceli R, Bonvalot S et al (2016) Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities: a retrospective analysis. Lancet Oncol 17:671–680CrossRefGoogle Scholar
- 18.Baracos VE, Arribas L (2018) Sarcopenic obesity: hidden muscle wasting and its impact for survival and complications of cancer therapy. Ann Oncol 1;29Google Scholar
- 26.Weinberg M, Shachar S, Deal A et al (2016) Characterization of skeletal muscle and body mass indices in younger and older women with stage II and III breast cancer. J Am Geriatr Soc supplement:S86Google Scholar
- 33.Grabowski JP, Richter R, Rittmeister H et al (2018) Impact of body mass index (BMI) on chemotherapy-associated toxicity in ovarian cancer patients. A pooled analysis of the north-eastern german society of gynecological oncology (NOGGO) databank on 1213 patients. Nticancer Res 38(10):5853–5858CrossRefGoogle Scholar